{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:47:36Z","timestamp":1794638856791,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 NS116824"],"award-info":[{"award-number":["R35 NS116824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00808","type":"journal-article","created":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T12:05:10Z","timestamp":1764504310000},"page":"e00808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment"],"prefix":"10.1016","volume":"23","author":[{"given":"Lorenzo","family":"Muccioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tappat\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"D'Agati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Angeloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Caravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cancellerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Minardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bisulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neurot.2025.e00808_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00808_bib3","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00808_bib5","volume":"21","author":"Colpaert","year":"2024","journal-title":"Neurological glycogen storage diseases and emerging therapeutics. Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00808_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jnc.15926","article-title":"The multifaceted roles of the brain glycogen","volume":"168","author":"Markussen","year":"2024","journal-title":"J Neurochem"},{"issue":"S2","key":"10.1016\/j.neurot.2025.e00808_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-021-01989-w","article-title":"Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis","volume":"16","author":"Pondrelli","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00808_bib8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00259-019-04647-3","article-title":"FDG-PET assessment and metabolic patterns in Lafora disease","volume":"47","author":"Muccioli","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.neurot.2025.e00808_bib9","doi-asserted-by":"crossref","first-page":"1202971","DOI":"10.3389\/fneur.2023.1202971","article-title":"Association of CSF and PET markers of neurodegeneration with electroclinical progression in Lafora disease","volume":"14","author":"d\u2019Orsi","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13023-019-1132-3","article-title":"Treatment with metformin in twelve patients with Lafora disease","volume":"14","author":"Bisulli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s13311-022-01304-w","article-title":"Early treatment with metformin improves neurological outcomes in Lafora disease","volume":"20","author":"Burgos","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00808_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00808_bib13","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00808_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00808_bib15","doi-asserted-by":"crossref","first-page":"110654","DOI":"10.1016\/j.yebeh.2025.110654","article-title":"The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness","volume":"171","author":"Williams","year":"2025","journal-title":"Epilepsy Behav"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00808_bib16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.molmed.2019.08.005","article-title":"Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases","volume":"25","author":"Zhou","year":"2019","journal-title":"Trends Mol Med"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00808_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.neurot.2025.e00808_bib18","doi-asserted-by":"crossref","first-page":"107317","DOI":"10.1016\/j.eplepsyres.2024.107317","article-title":"Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: relevance for clinical practice","volume":"200","author":"Zafra-Puerta","year":"2024","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00808_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic lafora bodies in lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00808_bib20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cmet.2021.05.003","article-title":"Brain glycogen serves as a critical glucosamine cache required for protein glycosylation","volume":"33","author":"Sun","year":"2021","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00808_bib21","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of Lafora disease","volume":"16","author":"Austin","year":"2019","journal-title":"Mol Pharm"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00808_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145875","article-title":"ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody","volume":"6","author":"Rattray","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00808_bib23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive glia-derived neuroinflammation: a novel hallmark in Lafora progressive myoclonus epilepsy that progresses with age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2025.e00808_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.seizure.2023.02.012","article-title":"Changes in serum blood-brain barrier markers after bilateral tonic-clonic seizures","volume":"106","author":"Cudna","year":"2023","journal-title":"Seizure"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00808_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612699","article-title":"Blood-brain barrier breakdown in neuroinflammation: current in vitro models","volume":"24","author":"Brandl","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00808_bib26","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol Genet Metabol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00808_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085062","article-title":"VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial","volume":"14","author":"Muccioli","year":"2024","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00808_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1528-1167.2006.00479.x","article-title":"Clinical and genetic findings in 26 Italian patients with Lafora disease","volume":"47","author":"Franceschetti","year":"2006","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00808_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/00207454.2024.2312992","article-title":"Characteristics of static balance performance in 4-stage balance test in the healthy older adults","volume":"135","author":"Wang","year":"2025","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/2150131916659282","article-title":"Timed up and Go (TUG) test: normative reference values for ages 20 to 59 years and relationships with physical and mental health risk factors","volume":"8","author":"Kear","year":"2017","journal-title":"J Prim Care Community Health"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00808_bib31","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.apmr.2017.04.004","article-title":"Six-minute walk test as a measure of walking capacity in ambulatory individuals with amyotrophic lateral sclerosis","volume":"98","author":"Sanjak","year":"2017","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.neurot.2025.e00808_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.109734","article-title":"Ten meter walk test for motor function assessment with technological devices based on lower members' movements: a systematic review","volume":"187","author":"Santos","year":"2025","journal-title":"Comput Biol Med"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00808_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00808_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12311-023-01543-3","article-title":"Scale for the assessment and rating of Ataxia (SARA): development of a training tool and certification program","volume":"23","author":"Grobe-Einsler","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.neurot.2025.e00808_bib35","first-page":"361","article-title":"The unified myoclonus rating scale","volume":"89","author":"Frucht","year":"2002","journal-title":"Adv Neurol"},{"key":"10.1016\/j.neurot.2025.e00808_bib36","series-title":"Leiter international performance scale","author":"Roid","year":"2013"},{"key":"10.1016\/j.neurot.2025.e00808_bib37","first-page":"199","article-title":"The vineland adaptive behavior scales","volume":"vol. 2","author":"Sparrow","year":"1989"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00808_bib38","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.neurot.2025.e00808_bib39","unstructured":"Natural history and functional status study of patients with Lafora disease (NCT03876522). Ionis Pharmaceuticals, Inc. Updated September 28, 2022. Accessed August 12, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03876522?cond=lafora&amp;rank=3."},{"key":"10.1016\/j.neurot.2025.e00808_bib40","article-title":"Pizzi E.,et al. Assessment of the potential use of VAL-1221 for Lafora disease: MS-based proteomics for the characterization and quantitation of the biotechnological drug in plasma and cerebrospinal fluid","volume":"21","author":"Esposito","year":"2025","journal-title":"MedRxiv Posted"},{"key":"10.1016\/j.neurot.2025.e00808_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/0471142727.mb3004s114","article-title":"Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling","volume":"114","author":"Fiehn","year":"2016","journal-title":"Curr Protoc Mol Biol"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00808_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood-brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.neurot.2025.e00808_bib43","series-title":"StatPearls. Treasure Island (FL)","article-title":"Ommaya reservoir","author":"Zubair","year":"2023"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in Parkinson\u2019s disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2025.e00808_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113595","article-title":"Mechanisms of receptor-mediated transcytosis at the blood-brain barrier","volume":"381","author":"Baghirov","year":"2025","journal-title":"J Contr Release"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00808_bib46","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/brain\/awab194","article-title":"Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease","volume":"144","author":"Ahonen","year":"2021","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00808_bib47","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s13311-023-01434-9","article-title":"Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease Mouse model","volume":"20","author":"Donohue","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00808_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat Rev Methods Primers"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:48:44Z","timestamp":1775306924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002867"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00808","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00808"}}